Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.
The services provided will cover Endpoint Detection and Response Service, SIEM Threat Detection Service, MDR Retained Incident Response, Managed Network Intruder Alarm Service, and a DDI Guard software.
A software license & maintenance agreement to enable MDC access to Genedata Screener software, specifically for the analysis of mass spectrometry experimental data, but also to be used for other data types such as compound screening.
The renewal of three, VAST 100TB/MO Gemini Services for our VAST Cluster, VAST-MDC-1 via Call-Off from the NHS SBS Digital Workplace Solutions Framework.
The contract is for Medicines Discovery Catapults Microsoft 365 Licence requirements and subsequent support procured under the CCS G-Cloud 13 framework
Marketing software to manage Medicines Discovery Catapults marketing campaigns, along with recording customer interactions and managing incoming enquiries.
Medicines Discovery Catapult required a managed detection and response and for an effective EDR tool. The EDR provision was evaluated on the basis of Mean Time to Detect (MTTD), ease
and speed of deployment within the Windows, Mac and Linux estate, detection capabilities (as scored by MITRE ATT&CK evaluations).
The tender was ran as a competition under the NHS SBS Digital Solutions framework.
A multi-drug resistant pathogen reference strain and clinical isolate collection representative of pathogens and resistance mechanisms directly aligned to the PACE first funding call that can be used by the provider to generate antimicrobial susceptibility data across PACE-funded projects and that can be made available to PACE awardees for onward project progression.
Continued expansion and characterisation of the strain and isolate collection to ensure it remains reflective of contemporary and genomically diverse multi-drug resistant and epidemic lineages of target pathogens (~20-30 strains) across E. coli, K. pneumoniae, P. aeruginosa, A. baumannii and S. aureus. This expanded collection will be made available for antimicrobial susceptibility testing (AST) across PACE-funded projects and the wider AMR community.
The Advanced Technologies team at the Medicines Discovery Catapult (MDC) is looking to expand its current advanced microscopy facility to support both our own growing needs and provide the UK SME community access to advanced molecular and cellular imaging.
MDC is aiming purchase a confocal High Content Screening (HCS) instrument based on an automated well-plate inverted microscope, together with confocal and widefield functionalities. It is crucial for the HCS system to be flexible and provide fast and high-resolution imaging of a wide range of experiments.
The instrument should be configured to enable the use of different sample formats (2D and 3D cell models, tissue sections, fixed and live-cell) and experimental types (drug dose responses, live-cell kinetic studies, phenotypic screening, RNA scope), using a large variety of well-plate formats and a wide range of fluorophores. In addition, the HCS instrument must be supplied with a high-end solution for high content image analysis, visualization and handling.